limitation of the study is that the costs of maintenance and the human resources reengineering required need to be further explored.

Abstract DSL-004 Table 1

<table>
<thead>
<tr>
<th>Advantages and disadvantages of the two systems</th>
<th>System A</th>
<th>System B</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAFETY</td>
<td>All DUs can be unequivocally identified with batch expiry date</td>
<td>Partial identification with batch code without batch code</td>
</tr>
<tr>
<td>Complete record, including batch, administration by scanner</td>
<td></td>
<td>SAFETY</td>
</tr>
<tr>
<td>Closed system</td>
<td>Partially open systems, error risks</td>
<td>SAFETY</td>
</tr>
<tr>
<td>EFFICIENCY</td>
<td>Entire integrated system including outpatients and elderly residences</td>
<td>Immediate availability of nursery doses needed to the patient</td>
</tr>
<tr>
<td>Full return of unmanaged DUs</td>
<td>Comprehensive system</td>
<td>EFFICIENCY</td>
</tr>
<tr>
<td>Allows automatic checking of expiry dates</td>
<td>Full expiry date control is difficult</td>
<td>EFFICIENCY</td>
</tr>
<tr>
<td>QUALITY</td>
<td>Complete record of all movements of both drugs and users</td>
<td>High cost</td>
</tr>
<tr>
<td>Additional cost per DU (euros)</td>
<td>0.19</td>
<td>0.20</td>
</tr>
</tbody>
</table>

No conflict of interest.

DSL-005 COMPARATIVE STUDY OF THE COST OF ERYTHROPOIETIC FACTORS, ORIGINAL MEDICINES AND BIOSIMILARS IN FRENCH CARE FACILITIES

doi:10.1136/ehjpharm-2013-000276.248

'D Karydakis, 'C Valet, 'F Bocquet, 'P Paubel. 'GROUPE HOSPITAUX PARIS SAINTE JOSEPH, Pharmacy, Paris, France; 'Agence Générale des Produits de Santé, Pharmacy, Paris, France; 'Université Paris-Descartes, Pharmacy, Paris, France

Background The patent expiries of leading biological products and the development of biosimilars create opportunities for cost savings. No studies have been carried out in the French hospital market.

Purpose To perform a cost saving modelling analysis and investigate the potential factors that could affect the price of drugs.

Materials and Methods We carried out a comparative study in French healthcare facilities, representing about 65% of national hospital beds, of the price of erythropoietic factors. The data were collected on procurement procedures operative as of 1 January 2012.

Results 25 care facilities agreed to participate in the study. The overall sales turnover reached €15 M. Biosimilars represent less than 1% market share. All the establishments granted a discount of between 5% and 69% on the prices fixed by negotiation between the Comité Économique des Produits de Santé and the manufacturers, depending on the category (drugs, biosimilars or original biopharmaceuticals). The average discounts ranged from 11% to 73%. Binocrit, the main biosimilar represented was 25.6% less expensive than its original medicine Eprex. Based on French hospital financing, we show a 24.7% cost saving if a high interchangeability rate is adopted. Some participants could save up to 50% of their budget.

We identified and analysed three criteria known to have a far-reaching effect on the drugs price. We observe no or little effect of the type of procurement procedure and specified quantity of medicine. The starting date of the contract is the primary criterion when purchasing drugs. The impact of these criteria varied depending on the drug in question and no general conclusions about medicines could be drawn.

Conclusions The market for biosimilars is growing at a faster rate than the global prescription-drug market. Many top-selling biologicals are due to lose patent protection over the next few years. The great potential for cost savings apparent in our study could be investigated in other countries.

No conflict of interest.

DSL-007 DOES PHARMACY CONTRIBUTE TO DELAYS IN HOSPITAL DISCHARGE?

doi:10.1136/ehjpharm-2013-000276.250

'V Marvos, S Kuo, D Linnard. Chelsea and Westminster Hospital, Pharmacy Dept, London, UK

Background Efficient management of patient flow including timely discharge from hospitals is vital. Patients in UK hospitals are commonly given individually labelled medicines to take home (TTOs). It is perceived by the multidisciplinary team at our hospital that waiting for these medicines is a significant rate-limiting step in the discharge process.

Purpose We examined the timeframes around TTO prescribing, dispensing and patient discharge in order to identify delays and any negative impact of the pharmacy processes involved.

Materials and Methods All TTO prescriptions entered into the pharmacy electronic log on one day in May 2012 were examined...
Drug supply/logistics

retrospectively. Once dispensed, TTOs are logged ‘off’ and sent by pneumatic chute system direct to the ward. This log and the hospital electronic prescribing system store relevant data including the time a TTO is written, dispensed and the patient discharged.

Results A total of 65 TTOs were dispensed in the pharmacy. (Others are prepared in a satellite unit, not included in this study). Only 18% were prescribed more than 24 hours before discharge. Writing of TTOs clustered around 11am–4pm whereas patient discharges were around 12–1pm and 2–6pm. Nearly 90% of TTOs were ready within 2 hours of the prescription being written. The average time from writing a TTO to the patient’s discharge was 2.5 hours. The average dispensing time per patient was 1.2 hours. The Pharmacy element accounted for less than half the time patients were waiting for TTOs.

Conclusions The perception that dispensing of TTOs is responsible for significant delays in patient discharge is unfounded. There is a lag time between TTOs being ready and the patient going home which merits further investigation. The clustering of TTO writing infers that very few are written until the morning ward rounds are finished. Options are being explored to encourage earlier writing times such as including TTO-transcribing pharmacists on consultants’ rounds.

No conflict of interest.

Conclusions Farmanco gives pharmacists up-to-date information on drug shortages in The Netherlands.

Finally, trends in drug shortages can be signalled.

No conflict of interest.

Conclusions Drug shortage has been reported since several years but has recently reached critical levels. Shortage occurs not only in Europe but worldwide, in all healthcare practise settings and affects potentially all drug classes, raw materials and medical devices. This combination of factors leads undoubtedly to medication overpricing and higher costs to the healthcare system, suboptimal clinical care, more medication errors and adverse events and the loss of patients’ lives. Rational and effective procurement of medicines in foreign countries can be a challenge for hospital pharmacists.

Purpose The objective is to present a framework on medicines importation, with a special focus on European countries.

Materials and Methods Web search on governmental healthcare institutions (i.e. medicines’ agencies), wholesalers, manufactures and other legal suppliers. This work was designed considering the Portuguese drug shortage.

Results A standard operation methodology was designed for searching for new suppliers for special medicines, not marketed or sold out. Search methodology on medicines’ agencies is presented. A short framework for suppliers was filled considering regulatory issues, current good manufacturing practises, place in the drug supply chain, logistics, packaging, pricing, taxes, expedition costs and payment conditions. Web links to suppliers’ websites are included.

Conclusions Importation of medicines at the hospital level is more often part of the daily tasks of pharmacists. When treating critical health conditions, shortages in essential medicines can cause disruptions in patients’ safety and quality of pharmacological treatment.

No conflict of interest.

Conclusions Drug shortages have increased in frequency from 91 reported in 2004 till 2011. Nevertheless, the Hospital did not have to invest in them since they were donated by a national foundation.

The ICU is comprised of a total of 42 dedicated critical care beds located in 3 different modules, and ED has 2 modules with a total of 22 beds and 9 chairs.

The ADSs are connected to hospital admission software and to the pharmacy management software.

Medication costs in ICU and ED were examined, comparing one year prior to installation with the years after implantation of the ADS. These data were obtained from the management software of the pharmacy department.